Michael Cloonan

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Cambridge, MA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
Jennifer Fitzpatrick, Attorney-in-Fact
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Michael Cloonan

Form 4 holding President & CEO, Director

Sionna Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
450,252
Estimated value
Report date
06 Feb 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding President & CEO, Director

Sionna Therapeutics, Inc.

Security class
Non-Qualified Stock Option (right to buy)
Shares / value
436,100
Estimated value
Report date
02 Jan 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

bluebird bio, Inc.

Security class
Stock Option (right to buy)
Shares / value
74,775
Estimated value
Report date
20 Jun 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Michael Cloonan

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .